Shang Jin, Previs Stephen F, Conarello Stacey, Chng Keefe, Zhu Yonghua, Souza Sandra C, Staup Michael, Chen Ying, Xie Dan, Zycband Emanuel, Schlessinger Karni, Johnson Victoria Plamadeala, Arreaza Gladys, Liu Franklin, Levitan Diane, Wang Liangsu, van Heek Margaret, Erion Mark, Wang Yixin, Kelley David E
Merck & Company, Incorporated, Kenilworth, New Jersey; and
Merck & Company, Incorporated, Kenilworth, New Jersey; and.
Am J Physiol Endocrinol Metab. 2017 Apr 1;312(4):E235-E243. doi: 10.1152/ajpendo.00398.2016. Epub 2017 Jan 31.
Insulin resistance and diabetes can develop spontaneously with obesity and aging in rhesus monkeys, highly similar to the natural history of obesity, insulin resistance, and progression to type 2 diabetes in humans. The current studies in obese rhesus were undertaken to assess hepatic and adipose contributions to systemic insulin resistance-currently, a gap in our knowledge-and to benchmark the responses to pioglitazone (PIO). A two-step hyperinsulinemic-euglycemic clamp, with tracer-based glucose flux estimates, was used to measure insulin resistance, and in an intervention study was repeated following 6 wk of PIO treatment (3 mg/kg). Compared with lean healthy rhesus, obese rhesus has a 60% reduction of glucose utilization during a high insulin infusion and markedly impaired suppression of lipolysis, which was evident at both low and high insulin infusion. However, obese dysmetabolic rhesus manifests only mild hepatic insulin resistance. Six-week PIO treatment significantly improved skeletal muscle and adipose insulin resistance (by ~50%). These studies strengthen the concept that insulin resistance in obese rhesus closely resembles human insulin resistance and indicate the value of obese rhesus for appraising new insulin-sensitizing therapeutics.
在恒河猴中,胰岛素抵抗和糖尿病会随着肥胖和衰老而自发出现,这与人类肥胖、胰岛素抵抗以及发展为2型糖尿病的自然病程高度相似。目前针对肥胖恒河猴开展的研究旨在评估肝脏和脂肪对全身胰岛素抵抗的影响——目前这方面存在知识空白——并确定对吡格列酮(PIO)的反应基准。采用两步高胰岛素-正常血糖钳夹技术,并基于示踪剂估计葡萄糖通量,来测量胰岛素抵抗,在一项干预研究中,在PIO治疗(3毫克/千克)6周后重复该操作。与瘦的健康恒河猴相比,肥胖恒河猴在高胰岛素输注期间葡萄糖利用率降低60%,脂肪分解抑制明显受损,这在低胰岛素和高胰岛素输注时均很明显。然而,肥胖代谢异常的恒河猴仅表现出轻度肝脏胰岛素抵抗。6周的PIO治疗显著改善了骨骼肌和脂肪胰岛素抵抗(约50%)。这些研究强化了肥胖恒河猴的胰岛素抵抗与人类胰岛素抵抗非常相似的概念,并表明肥胖恒河猴在评估新的胰岛素增敏疗法方面的价值。